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The relation between left afrial dimension measured by 
M-mode chocardiography and systemic embolization after 
valve replacement was exam 
patients with a prosthetic val 
of Veterans Affairs &operative Study on V 
Disease. Baseline characteristics including several measures 
of left atrial enlargement were compared for 31 patients 
who devdoped systemic embolism aad 366 who did not 
develop embolism during a 5 year follow-up eriod. Vari- 
ables that were significantly related to left atrial dimension 
or systemic embolixation i  univariate analyses were in- 
cluded with several others in a multiple logistic regression 
model. 
The incidence rate of systemic embolism was more than 
three times higher after mitral valve replacement than after 
aortic valve replacement (4.4 and 1.3 per 100 patient-years, 
Systemic embolism is a potentially catastrophic complica- 
tion of cardiac valve replacement. A number of risk factors 
for valve thrombosis and systemic embolism have been 
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other factors. Univariate 
univariate or multi 
emit em~ulism  
undergoing valve repiacement. 
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evaluated inpatients with native valve disease and in those 
having prosthetic valve replacement. These include atrial 
fibrillation (l-l I), history of prior embolism (I21, age (6,13), 
cigarette smoking (l4), elevated hemogiobin (7,141, mitral 
versus aortic valve replacement (6,9, E-21) and anticoagu- 
lation status (5,9, II ,20-26). In addition, some investigators 
have suggested that the presence of an enlarged left atrium 
may increase the risk of developing systemic embolism. 
However, the potential association between size of the left 
atrium and risk of embolization has not been adequately 
studied (12,23,27). 
The hypothesis that left atrial size might be related to risk 
of systemic embolism was first proposed by Madden in 1949 
(28). Somerville and Chambers (29) reported that the risk of 
systemic embolism was threefold greater in patients wit 
mitral stenosis who had an enlarged left atrial appendage 
on chest roentgenogram than in patients who had a smaller 
left atrial appendage. However, subsequent investigators 
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Stu es@. The two primary objectives of the 
ent of Veterans Affairs Coo 
eart Disease are i.) to identify, 
survival in patients with valvu?ar heart disea 
tion were enrolled frohm 14 Veterans Affairs m 
(see Appendix for principal investigators and participating 
was available before valve 
herwise, the study group was r 
patients without left atrra 
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Table 1. Comparison f Patients Undergoing Valve Replacement 
With (study group; n = 397) and Without (n = 698) Left Atrial 
Dimension Measurements 
Study 
Group 
In = 397) 
Patients 
Without LA 
Dimension 
Measurements 
(n = 698) 
Previous systemic embolism (%I 
Previous endocarditis (%) 
Previous MI (%) 
NYHA functional class (%) 
I 
II 
HI 
IV 
LA enlargement on chest X-ray (%) 
Transmurai MI (%) 
Atrial fihriltation (%) 
Stenotic coronary vessels (%I 
0 
I 
2 
3 
Age (yr)? 
PA systolic pressure (mm Hg)t 
Enddiastolic volume (ml)t 
7.6 7.0 
7.6 4.7 
19.4 17.2 
6.8* 4.6* 
25.3 20.3 
51.9 50.3 
16.0 22.1 
36.5 31.8 
15.8 13.4 
21.6 21.2 
53.6 53.0 
15.8 18.0 
13.7 14.6 
16.9 14.3 
59.2 + 0.4 59.0 * 0.3 
41.1 f I.0 39.0 f 0.7 
198.2 + 4.8 196.2 f 3.5 
*p C 0.05. tValues are reported as mean 2 standard error. LA = left 
atrial; MI = myocardial infarction; NYHA = New York Heart Association; 
PA = pulmonary artery. 
centrally by a trained technician using criteria proposed by 
the American Society o! Echocardiography (36). Briefly, the 
dimension was measured at aortic valve closure, using 
leading edge criteria, and included the posterior aortic wail. 
Left atria1 dimension was evaluated both as a continuous 
variable and a dichotomous variable. The criteria used for 
left atrial enlargement were left atrial dimension ~4 cm, left 
atrial dimension 25 cm, left atrial index 22 cm/m2 (left atria1 
dimension/body surface area in m*) and, as recommended by 
Brown et al. (37), a ratio of left atria1 dimension to aortic root 
diameter 81.17. 
Systemic embolism. After valve replacement, patients 
were seen at 6 month intervals, and standardized data forms 
that assessed valve-related complications (including sys- 
temic embolism) were completed by a physician, study nurse 
or technician. The data forms included objective items 
relevant to the definitions of valve-related complications. 
When a report of possible systemic embolism was elicited, 
hospital discharge summaries, pathologic reports of intra- 
vascular material removed at surgery and autopsy reports 
were obtained. Using these data, a physician subcommittee 
(see Appendix) determined, without knowledge ofprosthetic 
valve type, whether or not specified criteria for systemic 
embolism (and other valve-related complications) were sat- 
isfied. Ei:ch suspected valve-related complication was re- 
viewed and discussed by telephone conference cal 
consensus was obtained. The de~nitiQ~s ofsystem 
were: 
1) 
2) 
3) 
4) 
5) 
Cerebral-sudden onset of an objective neurolo 
that occurred >4g h after awakening from ane 
valve replacement and lasting >30 min. 
Renal-sudden onset of flank pain with hematuria an 
abnormal renal scan. 
Peripheral-sudden o set of a cold painful Pi 
of pulse. 
Coronary-myocardial ~~~a~ct~~ 
cardiopulmonary b pass for valve repla 
tient with previously demonstrated 
normal coronary arteries. 
Mesenteric-acute onset of bowel iufarction, witb throm 
boembolism diagnosed at surgery or autopsy. 
actors relat 
Hematologic, angiographic and hemodynamic variables and 
those obtained from the history, physical examination, chest 
roentgenogram and electrocardiogram (ECG) at baseline 
study were examined to evaluate the relati 
atria1 dimension and systemic embolis 
age, body surface area, previous histor 
lism, previous history of myocardial infarction, number of 
stenotic coronary vesseis, current smoking habits, New 
York Heart Association functional class, hemoglobin level, 
atrial fibrillation, left atria! e~~arg~rne~t on chest roentgeno- 
gram, left atria1 abnormality on the rest ECG, anticoagula- 
tion status, cardiac index, left ventricular ejection fraction, 
pulmonary artery systolic pressure, arterial systolic pres- 
sure, left ventricular end-diastolic dimension and systolic 
shortening fraction (percent shortening ofthe left ventricular 
end-diastolic dimension). 
From rhe preoperative ECG, atria1 fibrillation was cate- 
gorized as present or absent. Of 301 patients with preoper- 
ative and postoperative evidence of atria1 fibrillation or 
normal &us rhythm, 94% had no change in rhythm (36 
remained in atria1 fibrillation and 246 continued to have 
normal sinus rhythm); atrial fibrillation developed in 8 and 
reversion to normal sinus rhythm occurred in 11. Because 
the proportion of patients who had a change in rhythm was 
relatively small and because preoperative ECGs were avail- 
able for a greater proportion of the study group, preoperative 
rather than postoperative assessment of atrial fibrillation was 
used. 
Patients were considered tobe on anticoagulant therapy if
they reported taking an anticoagulant agent in any of the 
twice yearly follow-up interviews. Postoperative anticoagu- 
lation was recommended by research protocol to continue 
indefinitely for patients receiving a mechanical prosthesis 
and to be used 4 to 8 weeks for those receiving a biopros- 
thesis, unless there were clinical indications for its continued 
JAW Vo 
January I 
No. I 
2-41 LE ATRlAL SEE AND SY 
AQrtiC 253 II 855.8 1.3 
II2 16 368.4 4.4 
32 4 92.9 4.3 
sis of covariance was us 
baseline study, defined by left atrial 
left atria1 index 22 cm/m’, when all patients were COnS 
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Table 3. Mean Left Atria1 Dimension and Systemic Embolism Status by Site of Valve Replacement 
in 397 Patients 
EmboZsm Present Embolism Absent 
Valve 
Replacement No. of 
LA Dimension 
No. of 
LA Dimension 
Site Patients Mean SEM Patients Mean SEM p Value 
Acrtic 11 4.11 0.13 242 4.15 0.06 0.877 
Mitral 16 5.52 0.24 96 5.51 0.12 0.855 
Aortic and mitral 4 4.81 0.24 28 5.36 0.19 0.294 
Total 31 4.93 0.18 366 4.62 0.06 0.147 
LA = left atrial. 
tog&fir (Table 4). Differences were not significant for the 
other two measures of left atria1 enlargement (left atria1 
&nension r5 cm and left atria1 dimension divided by dortic 
root diameter -s1.17), although the trend was in the same 
direction. However, when incidence rates were examined 
within each valve location, the rate ratios comparing inci- 
dence in patients with and without left atrial enlargement 
were of smaller magnitude and no longer significant (as 
evidenced by 95% confidence intervals for the rate ratios 
that included the value 1 and the p values that were 3.2 for 
all comparisons involving an incidence rate of zero and, 
therefore, the lack of a 95% confidence interval). For several 
indexes of left atrid size, the number of patients and their 
patient-years of follow-up were small when analyses were 
stratified by valve location. Of 20 embolic episodes occur- 
ring in patients having isolated mitral valve replacement or 
both aortic and mitral valve replacement, all 20 were in 
patients with a left atria1 dimension 24 cm and the follow-up 
for patients with a left atria1 dimension ~4 cm was limited to 
20 patient-years (15 in the mitral and 5 in the aortic plus 
mitral valve replacement subgroups). 
Postoperative left atria! dimension. For 246 patients in 
whom measurements were available, mean postoperative 
left atria1 dimension did not differ significantly between 
patients who did or did not deve!op systemic embolism: this 
was true for those having aortic, mitral or multiple valve 
replacement and when all patients undergoing valve replace- 
ment were considered collectively. Left atrial dimension 
changed very little from the pre- to the postoperative p riod 
in patients undergoing aortic valve replacement, and de- 
creased an average of 0.5 to 0.6 cm in patients undergoing 
mitral valve replacement. These small changes in left atria1 
dimension from baseline to 6 months after operation were 
not statistically different when patients who did or did not 
develop systemic embolism were compared. 
Factors related to left atrial dimension and embolism. 
Incidence rates of systemic embolism were compared for 
patients with and without a nlmmber of potential risk factors 
for embolism. When all patients undergoing valve replace- 
ment were considered collectively, incidence rates were 
three times greater for patients in atrial fibrillation preoper- 
atively and for those who had a previous history of systemic 
embolism compared with patients without hese risk factors; 
differences were statistically significant for atria1 fib~~~atio 
(p = 0.002), were nearly significant for previous ystemic 
embolism (p = 0.07) but were nonsignificant wben compar- 
isons were made within valve location subgroups. Statisti- 
cally significant differences in the incidence of systemic 
embolism after valve replacement were ncl found when 
patients who were on warfarin anticoagulation, those with a 
history of myocardial infarction, those with stenotic  
nary vessels, those who smoked cigarettes orthose wbs 
a poorer functional class were compared with those lacking 
these risk factors for any of the subgroups or overall. In 
addition, the rate of systemic embolism did not differ signif- 
icantly for patients receiving a mechanical or tissue valve 
prosthesis. 
Among a number of continuous variables examined at 
baseline study (not shown), only age and left ventricular 
ejection fraction were significantly related to the develop 
ment of systemic embolism. Patients who developed sys- 
temic embolism tended to be younger than those who did 
not. These age differences were statistically significant for 
patients undergoing aortic valve replacement and for all 
subgroups combined. Left ventricular ejection fraction was 
significantly higher in patients with embolism than in those 
without embolism for the mitral subgroup and ~11 patients 
combined; ifferences were nearly significant Ip = 0.057) for 
the aortic subgroup as well. 
The mean left atrial dimension was significantly larger itz 
patients who had atrialfibrillntion at buseline than in those 
who had normal sinus rhythm (5.65 versus 4.43 cm, respec- 
tively; p = <O.OOl). Mean left atrial dimension was aiso 
significantly arger in patients who were than in those who 
were not on anticoagulant therapy after valve replacement 
(4.80 versus 4.39 cm, respectively; p = 0.001). These dB’er- 
ences were consistent for the aortic and mitral subgroups as 
well. Left atrial dimensiion did not vary significantly by age 
in this group, yet did increase with increasing body surface 
area. 
Multivariate analysis (Table 5). ‘IO rtxamio? the effect of 
left atria1 dimension ot; the risk of syst’ ;u;c embolism after 
I 
Enlargement 
Aortic 
LAD 
24 cm 
<4 c 
LAD 
2.5 cm 
<2 cm/mZ 
LAD/,?ortic dia 
21.17 
Cl.17 
itral 
LAD 
24 cm 
c4 cm 
E 
cm 
c5 cm 
LA index 
82 cmlm’ 
Cl.17 
Aortic and mitmi 
LAD 
24 cm 
CDl 
E 
25 cm 
<5 cm 
LA Index 
22 cmlil? 
c2 cm/m’ 
LAJaortic dia 
21.17 
Cl.17 
Total 
LAD 
=4 cm 
<4 cm 
LAD 
r5 cm 
<5 cm 
LA index 
e2 cm/m’ 
<2 Lm/m’ 
LADlaortic dia 
21.17 
<I.17 
7 
4 
47% 
37% 
I.5 
1.1 
0 
I1 
158 
697 
0 
1.6 
8 
3 
529 
323 
I.5 
0.9 
4 
7 
399 
440 
1.0 
I.6 
12 265 4.5 
4 96 4.2 
351 
10 
4.6 
0 
a 
I 
334 
25 
4.5 
4.0 
4 
0 
88 
5 
4.5 
0 
I 
3 
52 
41 
I.9 
7.3 
4 
0 
93 
0 
4.3 
0 
4 
0 
86 
7 
4.7 
0 
27 912 3.0 
4 398 I.0 
03 475 2.7 
18 835 2.2 
28 913 
3 334 
23 818 
8 472 
2.9 
0.9 
2% 
1.7 
1.4 
0 
I.6 
0.6 
0 
I.1 
0 
I.1 
0 
0.3 
0 
0 
2.9 
1.3 
3.2 
1.7 
0.4-4.7 
0.4-6.2 
0.2-2.2 
0.4-3.4 
0.1-11.5 
0. i-2.5 
I .o-8.4 
0.6-2.6 
1.0-10.5 
0.7-3.7 
“Confidence intervals were not calculated when rate ratios were zero: the incidence rates did not differ 
significantly (p > 0.2) for any of these comparisons. Cl = confidence interval for rate ratio: dia = diameter: LA = 
left atrial: LAD = left atrial dimension. 
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Table 5. Relation Between Left Atria1 Dimension and Systemic fi;mbolism After Valve 
Replacement by Logistic Regression Analysis* 
95% Confidence 
Regression Interval for 
Variable Coefficient SE Odds Ratio Odds Ratio p Value 
LA dimension -0.250 0.272 0.78 0.46-l .33 0.3579 
Atrial fibriiation 1.222 0.613 3.39 1.02-11.29 0.0461 
Anticoagulation 1.032 0.645 2.81 0.19-9.94 0.1097 
Prior embolism 0.930 0.891 2.53 0.44-14.53 0.2969 
Age -0.083 0.028 0.92 0.87. 3.97 0.0830 
Body surface area I.187 1.387 3.28 0.22-49.68 0.3923 
Ejection fraction 0.046 0.020 1.05 t.W-1.09 0.0207 
Valve location? 1.426 0.623 4.16 1.23-14.11 0.0221 
Valve type# 0.676 0.566 I .97 0.65-S.% 0.2325 
*The logistic re8ression model included 265 patients and 24 embolism cases: the regression coefficient for the 
intercept was -7.148; the -2 times log likelihood ratio chi-square statistic for this model was 31.172 with 9 degrees 
of freedom, with a corresponding p value of 0.0803 and r = 0.286. ‘Waive location = mitral Y ?h or without aortic 
valve replacement relative to aortic ” alve replacement only. SValve type = mechanical versus tissue prosthetic 
valve. LA = left atria!; SE = standard error of the regression coefficient. 
adjusting for several variables that could influence this 
relation, alogistic regression analysis was performed. Vati- 
ables that were univariately related to systemic embolism or 
lefi atrial dimension were included in the model; these were 
atrial fibrillation, age, body surface area, ejection fraction 
and location of valve replacement. The type of valve pros- 
thesis (mechanical or tissue) and left atria1 dimension were 
also included. Several variables were retained in the model 
regardless of statistical significance (anticoagulation, prior 
embolism and valve type) to adjust for potential confounding 
of the relation between left atrial dimension and systemic 
embolization. I  patients who underwent valve replacement, 
there was no evidence of an association between left atrial 
dimension and systemic embolism after controlling for the 
effects of other independent variables inthe logistic model. 
The negative regression coefficient and odds ratio <l indi- 
cates a slight inverse relation between left atria1 dimension 
and risk of embolism after adjusting for other pertinent 
variables. The odds ratio of 0.78 means that an increase of 
1 cm in left atrial dimension would be associated with a 22% 
reduction in the risk of systemic embolism. However, this 
relation was not statistically significant as indicated by the 
95% confidence interval for the odds ratio that includes a 
value of 1.0 (range 0.46 to 1.33) and the p value of 0.3579. 
native sys- 
temic embolism. This investigation was conducted to deter- 
mine whether preoperative l ft atria1 dimension was an 
independent predictor of subsequent systemic embolization 
in patients undergoing valve replacement. Our results indi- 
cate that he size of the left atrium does not influence the risk 
of systemic embolism when the location of valve replace- 
ment is taken into account. When left atria1 dimension is 
compared within prosthetic valve location categories (aortic, 
mitral and both aortic and mitral subgroups), it is 
that the mean preoperative l ft atrial dirne~si~~ was quite 
similar in patients who subsequently did or did not develo 
systemic embolism (Table 3). In addition, incidence rates in 
patients having an enlarged left atrium were not significantly 
different from incidence rates in patients with a left atrium of 
normal size (Table 4). In ~~iva~ate nalyses involving all 397 
patients combined, the risk of systemic embolism was sig- 
nificantly higher for patients having evidence of left atria1 
enlargement defined either as a left atrium ~-4 cm or as a left 
atria1 index 82 cm/m* (Table 4). Because the location of the 
prosthetic valve was strongly rtlated to both left atria1 
dimension (Table 3) and the risk of systemic embolism 
(Table 2), it is likely that the true relation between left atria1 
dimension and risk of systemic embolism was obscured by 
not taking into account the location of valve replacement. 
An indication of these relations i  provided by the foflow- 
ing observations: 1) the mean preoperative dimension of the 
left atrium was approximately 1.4 cm larger for patients 
having mitral than for those having aortic valve replacement; 
and 2) patients receiving a prosthetic valve in the mitral 
position were nearly four times more likely to develop 
systemic embolism than were patients who underwent aortic 
valve replacement. These findings are confirmed in the 
multivariate analyses using a logistic regression model (Ta- 
ble 5), which showed that left atria1 dimension was not 
related to the risk of systemic embolization after taking into 
account the effects of other pertinent variables. 
ent 0 II 
The echocardiographic te hniques used in this study to 
assess the relation between left atrial diameter and systemic 
embolism provide a more objective method than that pro- 
e dete~iuat~o~ f 
e ~isc~assi~catiou of e 
inatiom by using a subcom- 
e potential problem may be 
tu and in situ thrombosis, 
ecause most systemic eanboli in 
not clearly ~ist~~~~~sb in itu 
the Framingham Study (14) to increase directly with age. 
The opposite relation between age and systemic embolism 
was obsemd iru this study (as indicated by the negative age 
of the patients wbo w 
use at all visits. The ad 
~rotb~o~bi~ times was u 
owever, we feel it is unl s would have obscure 
relatiou between left at 
diversion and s 
with increasing ejectioa 
that the source of the 
ventricle because ~bol~zat~o~ from the left ventricle Would 
be associated with left ventricular dysfunction. LOChn Of 
the valve prosthesis was also a significant predictor of 
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embolism, with greater embolic risk being associated with 
mitral valve replacement than with aortic valve replacement. 
Conclusion. Preoperative l ft atria1 dimension as mea- 
sured by M-mode echocardiography does not appear to 
influence the risk of systemic embolism after valve replace- 
ment in participants of the Department of Veterans Affairs 
Cooperative Study on Valvular Heart Disease after adjust- 
ment for other elevant variables. 
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